Pharmaceutical Track and Trace Software: DSCSA Guide

Pharmaceutical Track and Trace Software: Complete DSCSA Compliance Guide for Distributors

The Drug Supply Chain Security Act (DSCSA) requires all wholesale drug distributors to implement electronic, interoperable track and trace systems by November 27, 2024. As of that date, distributors must capture and transmit product-level serialization data, verify product identifiers, and respond to verification requests within 24 hours—capabilities that manual processes cannot support at scale.

Regulatory Background

The DSCSA, enacted under Title II of the Drug Quality and Security Act of 2013, established a phased framework to create an electronic, interoperable system for identifying and tracing prescription drugs as they move through the U.S. commercial distribution chain. The law applies to manufacturers, repackagers, wholesale distributors, and dispensers.

Section 582 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 360eee-1) defines the requirements for product tracing, product identifiers, authorized trading partners, and verification systems. The final enforcement deadline—November 27, 2024—marked the transition from lot-level tracking to unit-level serialization. After this date, distributors must be able to trace individual packages using a standardized numerical identifier (SNI), lot number, expiration date, and National Drug Code (NDC).

The FDA finalized guidance on DSCSA implementation in February 2023, clarifying verification obligations, interoperability standards, and the role of third-party solution providers. FDA has authority to inspect distributor systems for compliance under 21 U.S.C. § 360eee-3 and can issue warning letters or take enforcement action against distributors that fail to maintain required transaction histories and transaction statements in electronic format.

System Requirements Under DSCSA

Track and trace software must perform four core functions to satisfy DSCSA compliance:

1. Product Identifier Verification (PIV)

Distributors must verify the product identifier on each package or homogeneous case received from a trading partner. This includes scanning the 2D barcode containing the SNI, NDC, lot number, and expiration date, then confirming the data against the transaction information (TI) provided by the upstream trading partner. Under 21 CFR 582(d)(4)(C), verification must occur before the product is further distributed.

2. Transaction Information Storage and Transmission

Distributors must capture and store transaction information, transaction history (TH), and transaction statements (TS) in electronic, interoperable format for six years. When transferring product ownership, the distributor must provide the receiving trading partner with TI/TH/TS within one business day of the transaction. Manual spreadsheets or paper records do not meet the interoperability requirement.

3. Saleable Returns Verification

When accepting product returns, distributors must verify the product identifier and confirm the product is not counterfeit, diverted, or subject to a recall. The DSCSA requires verification to occur within 24 hours of receiving a saleable return request.

4. Investigation and Quarantine

If a distributor cannot verify a product identifier or identifies a suspect product, the DSCSA mandates investigation within five business days and quarantine of the product until verification is complete or the product is determined to be illegitimate.

Interoperability Standards

The DSCSA does not prescribe specific software platforms, but it requires electronic data exchange using standardized formats. Most track and trace systems implement the GS1 EPCIS (Electronic Product Code Information Services) standard for serialization data exchange. The system must support ATP (Authorized Trading Partner) verification through the FDA's National Directory or an equivalent third-party verification service.

Distributors using legacy warehouse management systems (WMS) must either upgrade those systems to support DSCSA data fields or implement middleware that connects the WMS to a dedicated DSCSA compliance platform. Point-to-point integration between a distributor and each trading partner is not scalable—most distributors use a centralized router or VAN (value-added network) to exchange transaction data with hundreds of upstream manufacturers and downstream pharmacies.

Operational Impact on Wholesale Distributors

For distributors handling high product volumes, DSCSA compliance represents a significant operational shift. Receiving workflows now include barcode scanning and real-time verification against transaction data. This adds processing time per unit received—distributors report verification cycles ranging from 2 to 15 seconds per package depending on system performance and connectivity to trading partner databases.

Distributors without pharmaceutical track and trace software in place face three compliance risks: (1) inability to verify product identifiers within required timeframes, exposing the operation to distribution of counterfeit or diverted product; (2) failure to maintain interoperable transaction records, which FDA can cite during inspections; and (3) inability to respond to verification requests from downstream trading partners within 24 hours, which disrupts the supply chain and may result in returned shipments.

State boards of pharmacy have begun incorporating DSCSA compliance into wholesale distributor license renewal inspections. Ohio, California, and Florida have issued guidance requiring distributors to demonstrate functional track and trace systems during facility inspections.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors, 3PLs, and cold chain providers across 51 U.S. jurisdictions. Of these entities, 1,234 hold active FDA registration—a prerequisite for DSCSA compliance but not sufficient on its own. FDA registration confirms an entity is known to the agency; it does not verify that the entity has implemented functional track and trace systems.

The average compliance score across all tracked entities is 51/100, placing the industry median in the "Fair" tier. The score distribution shows 28 entities (2.2%) in the Excellent range (80-100 points), 281 entities (22%) in the Good range (60-79 points), and 919 entities (72%) in the Fair range (40-59 points). This concentration in the Fair tier reflects a compliance posture common among mid-size regional distributors: state licenses and FDA registration are in place, but NABP accreditation and verified third-party certifications are less common.

Only 63 entities in the directory hold NABP accreditation (formerly VAWD), which includes a facility inspection and review of operational procedures. While NABP accreditation is not required under DSCSA, distributors with accreditation have typically undergone more rigorous compliance audits than non-accredited peers. The low accreditation rate (4.9% of tracked entities) suggests that most distributors rely on state board of pharmacy inspections as their primary external compliance verification.

ColdChainCheck tracks 73 entities with at least one FDA recall on record. Recalls are not direct indicators of DSCSA compliance—products can be recalled for manufacturing defects unrelated to serialization. However, recalls do trigger DSCSA verification obligations: distributors must cross-reference recall notices against inventory, quarantine affected lots, and notify downstream trading partners. Entities with multiple recalls may face closer FDA scrutiny of their track and trace procedures during inspections.

Practical Guidance for QA and Procurement Teams

• Verify trading partner DSCSA readiness: Before onboarding a new wholesale distributor or 3PL, confirm the entity can provide transaction information in EPCIS format and respond to verification requests within 24 hours. Use the ColdChainCheck directory to check FDA registration status and review enforcement history.

• Review entities with low compliance scores: Entities scoring below 40 points typically lack verified accreditations or have enforcement actions on record. A low score does not disqualify an entity, but it signals the need for enhanced due diligence—request documentation of DSCSA system implementation and ATP verification processes.

• Monitor recall patterns: Distributors with multiple recalls in the past 24 months may indicate supply chain control issues. Cross-reference ColdChainCheck recall data with your own vendor risk assessments to identify entities requiring closer monitoring.

• Document verification workflows: During audits, state boards of pharmacy and FDA inspectors expect distributors to demonstrate how they verify product identifiers and handle suspect products. Maintain records of verification requests sent to trading partners and response times. ColdChainCheck compliance scores are informational—they do not replace required ATP verification through FDA's National Directory.

ColdChainCheck tracks DSCSA-related enforcement actions and updates entity compliance scores as new data becomes available. For broader regulatory context on wholesale distributor requirements, see the compliance guides section.

Disclaimer: This article provides informational content based on publicly available regulatory data. It is not legal or compliance advice. Wholesale distributors should consult qualified legal counsel and regulatory advisors to ensure DSCSA compliance specific to their operations.